Phaseline

Targets › RPLC

RPLC: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on RPLC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Huashan HospitalLinezolid
Bacterial 70S ribosome inhibitor
RPLCPhase 3Multidrug Resistant Tuberculosis; Drug-resistant TuberculosisDec 2026
The Aurum Institute NPCSutezolid
Oxazolidinone antibiotic; inhibits bacterial protein synthesis by binding to the 50S ribos
RPLCPhase 2Tuberculosis–

Conditions

Multidrug Resistant Tuberculosis (1) Drug-resistant Tuberculosis (1) Tuberculosis (1)

Modalities

small molecule (1)

Companies

Huashan Hospital (1) The Aurum Institute NPC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.